SCHEDULE: Farallon Capital Adjusts Protagonist Therapeutics Stake

Farallon Capital Management, L.L.C. and associated entities have reported a beneficial ownership of 9.99% in Protagonist Therapeutics, Inc. as of June 30, 2026.

Summary

• Farallon Capital Management, L.L.C. and related entities (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of Protagonist Therapeutics, Inc. common stock.
• As of June 30, 2026, the Reporting Persons beneficially owned 6,348,906 shares of common stock.
• Additionally, they hold 1,500,000 common stock purchase warrants, with a Beneficial Ownership Limitation restricting exercise to 84,213 shares to maintain ownership below 9.99%.
• The total beneficial ownership, considering exercisable warrants, is reported as 6,433,119 shares, representing 9.99% of the class of securities.
• The filing clarifies that the Reporting Persons acquired these securities in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage to just under the 10% threshold, without indicating new strategic actions or significant financial performance.

Positives

• Farallon Capital Management maintains a significant, though just under the 10% threshold, stake in Protagonist Therapeutics, Inc., suggesting continued confidence or strategic interest.
• The clear disclosure of ownership and warrant holdings provides transparency to the market regarding a major institutional investor's position.

Negatives

• The filing does not provide any information on the company's financial performance, strategic initiatives, or future outlook, limiting insights into the company's operational health.
• The Beneficial Ownership Limitation on warrants indicates a capped upside potential for the Reporting Persons through warrant exercise without triggering further disclosure requirements.

Risks

• The Beneficial Ownership Limitation on warrants means that a significant portion of the warrants held by Farallon Funds (1,415,787) are not currently exercisable within 60 days, limiting immediate potential share acquisition.
• Future regulatory changes or shifts in ownership could impact the Reporting Persons' ability to hold or exercise their securities.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Protagonist Therapeutics, Inc.'s future performance or strategy. It solely reports on the beneficial ownership of securities by Farallon Capital Management and its affiliates.

Management Comments

• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors adjusting their holdings. Farallon Capital Management is a well-known investment firm, and their stake, while significant, remains just below the 9.99% threshold that would trigger more stringent reporting requirements (Schedule 13D). This filing provides a snapshot of their investment position without revealing underlying strategic motivations.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception. The 9.99% ownership level is notable but does not immediately suggest a change in control.
• Management: The filing confirms that the Reporting Persons are not acquiring shares with the intent to influence control, which may be reassuring to current management.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Farallon Capital Management will continue to monitor its holdings and may file amendments to this Schedule 13G if there are any material changes in beneficial ownership.
• Protagonist Therapeutics, Inc. will continue its business operations, the details of which are not disclosed in this filing.

Key Dates

Keywords

Protagonist Therapeutics, Farallon Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Institutional Investor, Securities Exchange Act